FDA Approves New Nasal Spray Medication for Treatmentresistant Depression

FDA Approves New Nasal Spray Medication for Treatment-resistant Depression

09:00 EST 7 Mar 2019 | Pharmaceutical Processing

News
The FDA has approved Spravato (esketamine) nasal spray, in conjunction with an oral antidepressant, for the treatment of depression in adults.
Contributed Author: 
Topics: 
Supply Chain

More From BioPortfolio on "FDA Approves New Nasal Spray Medication for Treatment-resistant Depression"